Literature DB >> 10840080

Fibroblast growth factor 2: its structure and property, paracrine function, tumor angiogenesis, and prostate-related mitogenic and oncogenic functions.

J K Dow1, R W deVere White.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2000        PMID： 10840080     DOI： 10.1016/s0090-4295(00)00457-x

Source DB:  PubMed          Journal:  Urology        ISSN： 0090-4295            Impact factor:   2.649


× No keyword cloud information.
  21 in total

Review 1.  Systems biology of the microvasculature.

Authors:  Lindsay E Clegg; Feilim Mac Gabhann
Journal:  Integr Biol (Camb)       Date:  2015-04-02       Impact factor: 2.192

2.  A vaccine targeting basic fibroblast growth factor elicits a protective immune response against murine melanoma.

Authors:  Xiaoping Zhang; Neng-Lian Li; Chao Guo; Ying-Dong Li; Lu-Lu Luo; Yong-Qi Liu; Yun-Yan Duan; Zhen-Dong Li; Xiao-Rong Xie; Hai-Xia Song; Li-Ping Yang; Fang-Yu An
Journal:  Cancer Biol Ther       Date:  2018-03-06       Impact factor: 4.742

3.  Circulating fibroblast-like cells in men with metastatic prostate cancer.

Authors:  Michelle L Jones; Javed Siddiqui; Kenneth J Pienta; Robert H Getzenberg
Journal:  Prostate       Date:  2012-06-21       Impact factor: 4.104

4.  TGF-β induction of FGF-2 expression in stromal cells requires integrated smad3 and MAPK pathways.

Authors:  Douglas W Strand; Yao-Yun Liang; Feng Yang; David A Barron; Steven J Ressler; Isaiah G Schauer; Xin-Hua Feng; David R Rowley
Journal:  Am J Clin Exp Urol       Date:  2014-10-02

5.  Expression of basic fibroblast growth factor correlates with resistance to paclitaxel in human patient tumors.

Authors:  Yuebo Gan; M Guillaume Wientjes; Jessie L-S Au
Journal:  Pharm Res       Date:  2006-06-08       Impact factor: 4.200

6.  A novel monoclonal antibody to fibroblast growth factor 2 effectively inhibits growth of hepatocellular carcinoma xenografts.

Authors:  Lihong Wang; Hangil Park; Sophea Chhim; Yi Ding; Wei Jiang; Cary Queen; K Jin Kim
Journal:  Mol Cancer Ther       Date:  2012-02-16       Impact factor: 6.261

7.  Increased serum concentrations of estrogen-induced growth factors Midkine and FGF2 in NF1 patients with plexiform neurofibroma.

Authors:  Isis Atallah; Ana M Cieza Rivera; Octavio M Rivero Lezcano; Laura Tascón-González; Carolina González-Cortés; Cristina Diez Tascón; Tania Fernández-Villa; Vicente Martín
Journal:  Am J Transl Res       Date:  2022-05-15       Impact factor: 3.940

8.  Polymorphisms in the FGF2 gene and risk of serous ovarian cancer: results from the ovarian cancer association consortium.

Authors:  Sharon E Johnatty; Jonathan Beesley; Xiaoqing Chen; Amanda B Spurdle; Anna Defazio; Penelope M Webb; Ellen L Goode; David N Rider; Robert A Vierkant; Stephanie Anderson; Anna H Wu; Malcolm Pike; David Van Den Berg; Kirsten Moysich; Roberta Ness; Jennifer Doherty; Mary-Anne Rossing; Celeste Leigh Pearce; Georgia Chenevix-Trench
Journal:  Twin Res Hum Genet       Date:  2009-06       Impact factor: 1.587

Review 9.  DPPIV/CD26: a tumor suppressor or a marker of malignancy?

Authors:  Aline Beckenkamp; Samuel Davies; Júlia Biz Willig; Andréia Buffon
Journal:  Tumour Biol       Date:  2016-03-04

10.  Chemopreventive effect of Korean Angelica root extract on TRAMP carcinogenesis and integrative "omic" profiling of affected neuroendocrine carcinomas.

Authors:  Jinhui Zhang; Lei Wang; Yong Zhang; Li Li; Suni Tang; Chengguo Xing; Sung-Hoon Kim; Cheng Jiang; Junxuan Lü
Journal:  Mol Carcinog       Date:  2014-10-12       Impact factor: 4.784
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.